Vasculotoxic Effects of Insulin and Its Role in Atherosclerosis: What is the Evidence?
Tóm tắt
As a result of ambiguous results from several recent trials in diabetes, scrutiny has focused on the potential effects of insulin and its role in atherosclerosis. This article reviews the premise that anti-diabetes therapy (type 2 diabetes) with insulin causes vascular impairment that leads to atherothrombosis and compromises vascular integrity, which may further potentiates cardiovascular morbidity and mortality. Underlying mechanisms are discussed, including metabolic derangements (blood pressure, lipids, body weight, and glucose) and how these factors trigger insulin-like growth factor (IGF) receptors, leading to cancer. Cellular and molecular mechanisms are discussed, as well as whether the negative results seen in recent glucose trials support this premise. As with most drug therapy, aggressive therapies designed to reach glucose control targets trigger multiple and inter-related mechanisms that, in many cases, go far beyond the pre-determined physiologic targets. From a clinical perspective, physicians should always stress lifestyle modifications, including physical exercise and diet, to their patients who show the first signs of metabolic impairment. Yet even within this context, diet and exercise should be the cornerstone of good therapy when pharmacotherapy is necessary. Given the amount of evidence seen to date with existing agents and the amount of information we do not yet know, patient-centered approaches to modifying behavior before intensive drug therapy are needed should be stressed.
Tài liệu tham khảo
• Faramarz Ismail-Beigi MD, Timothy Craven MSPH, Mary Ann Banerji MD, Jan Basile MD. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. The Lancet, Volume 376, Issue 9739, Pages 419–30. This trial brings into question the protection of microvascular events with good glucose control. Thoughtful questions arise in this recent publication with comparison to older trials.
• Brown A, Reynolds LR, Bruemmer D. Intensive glycemic control and cardiovascular disease: an update. Nat Rev Cardiol. 2010 Jul;7(7):369–75. This is an excellent quick overview of the recent trials using intensive glycemic control. It has quick charts to read with important contrasts between trials.
Schernthaner G. Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Wien Med Wochenschr. 2010 Jan;160(1–2):8–19.
Carlson MG, Campbell PJ. Intensive insulin therapy and weight gain in IDDM. Diabetes 1993;42:1700–07.
Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes—causes,effects and coping strategies. Diabetes Obes Metab. 2007 Nov;9(6):799–812. Review.
Greet Van den Berghe. J. Clin. Invest. 114:1187–95 (2004).
The DCCT Research Group. Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. Diabetes Care. 1988;11:567–73.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
Randeree H, Omar M, Motala A, Seedat M. Effect of insulin therapy of blood pressure NIDDM patients with secondary failure, Diabetes Care. 1992;15:1258–63.
Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA. 1998 Jul 8;280(2):140–6. Erratum in: JAMA 1998 Nov 4;280(17):1484.
Matsumoto M, Han S, Kitamura T, Accili D. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest. 2006 Sep;116(9):2464–72. Epub 2006 Aug 10.
Unger RH. How obesity causes diabetes in Zucker diabetic fatty rats. Trends Endocrinol Metab. 1997 Sep;8(7):276–82.
Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 2008 Feb;7(2):95–6. Review.
Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635–41.
Emanuele N. Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Arch Intern Med. 1998;158:2485-90.
Bastard JP, Piéroni L. Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity. Biomed Pharmacother. 1999 Dec;53(10):455–61.
Coughlin SS et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159:1160–7.
Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate and pancreas. Gastroenterology. 2007;132:2208–25.
Larsson SC, Orsini N, Wolk A. Diabetes and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(1679–1687):3.
Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92(2076–2083):4.
Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007;121:856–62.
Bowker SL et al. Increased cancer-related mortality for patients with T2D who use sulfonylureas or insulin. Diabetes Care. 2006;29:254–8.
Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia. 2009 Sep;52(9):1745–54. Epub 2009 Jul 9.
Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009 Sep;52(9):1766–77. Epub 2009 Jul 2.
Colhoun HM; SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009 Sep;52(9):1755–65. Epub 2009 Jul 15.
Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004 Apr 24;363(9418):1346–53. Review.